New adult and adolescent tuberculosis vaccines and Indonesia: policy planning and evidence, November 2024.

This report summarizes the proceedings of a policy and planning meeting convened in Indonesia, by the Ministry of Health and the World Health Organization, on potential new tuberculosis (TB) vaccines intended for adults and adolescents. Given that Indonesia bears the second highest TB burden globally, and that it is participating in the phase III efficacy study for one of the leading vaccine candidates that could be approved for use by 2028, the meeting aimed to discuss strategies and evidence needs that could accelerate vaccine introduction. The meeting, held in November 2024, was attended by Indonesian policymakers, researchers, health advocates and community representatives, alongside observers from immunization and TB programmes working at the global level, as well as donors.

Predictive factors of patient length of stay with multiloculated pleural effusion after medical thoracoscopy: single-center retrospective cohort study.

Background: Loculated pleural effusion (PE) is a complex condition that often necessitates thoracoscopy due to diagnostic and therapeutic challenges. This study aimed to identify factors influencing the length of stay (LoS) after rigid medical thoracoscopy for loculated PE and assess clinical outcomes, including improvements in lung function.

Method: This was a retrospective cohort study conducted at St.

Vaccine effectiveness of inactivated and mRNA COVID-19 vaccine platform during Delta and Omicron wave in Jakarta, Indonesia: A test-negative case-control study.

Background: Vaccination was included in the Indonesian government policy to address Delta and Omicron waves of SAR-CoV-2 infections. This study assesses the effectiveness of inactivated (CoronaVac, BBIBP-Cor) and mRNA vaccines (mRNA-1273, BNT162b2) against COVID-19 regardless of symptoms and fatal COVID-19 (mortality within 30 days after confirmed RT-PCR) during Delta and Omicron period in Jakarta, Indonesia.

Methods: This study case-control, test-negative study included all individuals aged over 18 years in Jakarta with complete and consistent SARS-CoV-2 RT-PCR results from 1 June to 31 August 2021 (Delta period) and 1 January to 2 April 2022 (Omicron period), as well as complete vaccination status.

Real-World Effectiveness of COVID-19 Vaccines (ChAdOx-1s, CoronaVac, BBIBP-CorV, mRNA-1273, and BNT162b2) in Jakarta: Protocol for Test-Negative Design of Health Care Data.

Background: ChAdOx-1s, CoronaVac, BBIBP-CorV, mRNA-1273, and BNT162b2 are the five common COVID-19 vaccines used in Jakarta. Randomized controlled trials have provided robust evidence of the safety and efficacy profile of these vaccines, but their real-world vaccine effectiveness against symptomatic COVID-19 and deaths in communities with social inequalities and health care constraints remains unclear.

Objective: This study aims to evaluate the real-world effectiveness of these COVID-19 vaccines during the waves associated with the Delta and Omicron variants by analyzing existing electronic health care sources.

Risk factors for viral hepatitis in pulmonary tuberculosis patients undergoing treatment: A systematic review and meta-analysis.

Liver injury in tuberculosis patients, associated with noncompliance with treatment, is further exacerbated by viral hepatitis, which not only directly harms the liver but also increases susceptibility to drug-induced liver injury. The aim of this study was to analyze the associated risk factors for viral hepatitis in tuberculosis patients. This systematic review and meta-analysis adhere to the PRISMA 2020 statement, and the protocol has been registered with PROSPERO (CRD42023477241).